chloroquine and derivatives for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
HYDRA (Hernandez-Cardenas) NCT04315896		RCT	hydroxychloroquine	placebo	COVID-19 severe or critically	some concern	106/108	inconclusive	inconclusive 20 % decrease in deaths,deaths (time to event analysis only),death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
3 studies excluded by filtering options (1 RCT / 2 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis